Company Filing History:
Years Active: 1992
Title: Sumiko Mizuno: Innovator in Endermic Medicaments
Introduction
Sumiko Mizuno is a prominent inventor based in Niigata, Japan. She has made significant contributions to the field of medicinal formulations, particularly with her innovative approach to endermic medicaments.
Latest Patents
Mizuno holds a patent for an endermic medicament with a gel base. This novel medicament is formulated using a non-ionic water-soluble cellulose ether, such as methyl cellulose and hydroxypropyl methyl cellulose. The formulation includes a modification agent that contains an alkyl group with 6 to 26 carbon atoms and a functional group that reacts with the hydroxyl group in the cellulose ether. The result is a stable gel that minimizes interaction between the active ingredients and the gel base, allowing for high percutaneous absorption of the active ingredients through human skin.
Career Highlights
Sumiko Mizuno is associated with Shin-Etsu Chemical Co., Ltd., where she has been able to apply her expertise in developing innovative medicinal products. Her work has been recognized for its potential to enhance the effectiveness of topical treatments.
Collaborations
Mizuno has collaborated with notable colleagues, including Sakae Obara and Hiroaki Muto, to advance her research and development efforts in the field of medicinal formulations.
Conclusion
Sumiko Mizuno's contributions to the field of endermic medicaments highlight her innovative spirit and dedication to improving healthcare solutions. Her work continues to influence the development of effective medicinal products.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.